Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that
compromises their immune response to infections and vaccines. For this reason, SOT …

Introduction Treatment of severe COVID-19 disease can be challenging in
immunocompromized patients due to newly emerging virus variants of concern (VOC) …

The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …

Since its outbreak in December 2019, the coronavirus disease 2019 (COVID-19) pandemic,
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), led to an …

Adoptive T cell immunotherapy has been used to restore immunity against multiple viral
targets in immunocompromised patients after bone-marrow transplantation and has been …

In the current post-pandemic era, recipients of an allogeneic hematopoietic stem cell
transplant (HCT) deserve special attention. In these vulnerable patients, vaccine …

Solid organ transplant (SOT) recipients receive immunosuppressive drugs (ISDs) and are
susceptible to developing severe COVID-19. Here, we analyze the Spike-specific T-cell …

Background. The ability of transplant (Tx) patients to generate a protective antiviral response
under immunosuppression is pivotal in COVID-19 infection. However, analysis of immunity …

Therapeutic management of solid organ transplant (SOT) recipients infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease …

The coronavirus disease 2019 (COVID-19) pandemic has posed significant global
challenges for solid organ transplant (SOT) recipients. Mortality rates of COVID-19 in this …